Bing

SEARCH HISTORY

As a result of litigation settlements, however, investors can expect generic substitutes from Impax Labs (IPXL) and Mylan (MYL ... Year-to-date, Pfizer has bought back $8.7 billion in common stock – a buyback yield of 4.8% -- up from $8.3 billion ...
YCharts · 8/20/2013
Impax Laboratories (IPXL): is our top small-cap name with upside expected from H1/12 catalysts likely to reverse negative sentiment and growing focus on a more robust EPS story in 2013. MAP Pharmaceuticals (MAPP): is our favorite catalyst-driven stock
Forbes · 1/17/2012
Impax Labs (NASDAQ:IPXL ... Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or ...
Minyanville · 6/7/2014
HAYWARD, Calif., April 21, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its Board of Directors has appointed G. Frederick Wilkinson as Impax's President and Chief Executive Officer effective April 29, 2014. Mr ...
Stockhouse · 4/21/2014
The companies have faced patent challenges by other generic drug makers, including Impax Laboratories Inc. (IPXL) in November ... of Arrow Group for about $1.7 billion in cash and stock. In November, the drug maker reported its third-quarter profit ...
Automated Trader · 1/25/2011
The FDA just approved AbbVie's ($ABBV) novel formulation of the standard ... Indeed, the FDA's approval comes on the heels of this month's green light for Impax Laboratories' ($IPXL) Rytary, which contains immediate- and extended-release beads of …
Fierce Drug Delivery · 1/12/2015
Impax Laboratories ($IPXL) has enough on its plate trying to get its manufacturing ... This led Impax to say it would have to delay the launch of several key drugs. Of course, the stock took a hit. The suit said, "As a result of this news, Impax's stock ...
Fierce Pharma Manufacturing · 9/25/2014
Impax Laboratories ($IPXL) is on a roll. The Hayward ... And investors cheered the biiopharma company on to the regulatory finish line by pumping up the company's stock by 12 percent, adding to a months-long surge in the price. The primary endpoint ...
Fierce Biotech · ByJohn Carroll · 3/15/2011
Endo's stock is up to a record high since last week's deal announcement. So, analysts are speculating about which buyout's next for Endo--BioDelivery Sciences ($BDSI), say? Or the generics maker Impax Laboratories ($IPXL)? In announcing last week's …
FiercePharma · ByTracy Staton · 11/13/2013
--(BUSINESS WIRE)--Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has ... results of operations and market value of its common stock, the ability to maintain an effective system ...
Business Wire · 8/25/2010